Literature DB >> 18165631

Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?

Noah D Kauff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18165631     DOI： 10.1200/JCO.2007.14.0244

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer.

Authors:  David M Hyman; David R Spriggs
Journal:  JAMA       Date:  2012-01-25       Impact factor: 56.272

2.  Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.

Authors:  David J Gallagher; Angel M Cronin; Matthew I Milowsky; Michael J Morris; Jasmine Bhatia; Peter T Scardino; James A Eastham; Kenneth Offit; Mark E Robson
Journal:  BJU Int       Date:  2011-07-14       Impact factor: 5.588

3.  BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

Authors:  Pierosandro Tagliaferri; Monica Ventura; Francesco Baudi; Iole Cucinotto; Mariamena Arbitrio; Maria Teresa Di Martino; Pierfrancesco Tassone
Journal:  J Ovarian Res       Date:  2009-10-13       Impact factor: 4.234

4.  Stemming the tide of cancer for BRCA1/2 mutation carriers.

Authors:  Henry T Lynch; Joseph N Marcus; Wendy S Rubinstein
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

Review 5.  Making the best of PARP inhibitors in ovarian cancer.

Authors:  Susana Banerjee; Stan B Kaye; Alan Ashworth
Journal:  Nat Rev Clin Oncol       Date:  2010-08-10       Impact factor: 66.675

6.  High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients.

Authors:  Evgeny N Suspitsin; Nathalia Yu Sherina; Daria N Ponomariova; Anna P Sokolenko; Aglaya G Iyevleva; Tatyana V Gorodnova; Olga A Zaitseva; Olga S Yatsuk; Alexandr V Togo; Nathalia N Tkachenko; Grigory A Shiyanov; Oksana S Lobeiko; Nadezhda Yu Krylova; Dmitry E Matsko; Sergey Ya Maximov; Adel F Urmancheyeva; Nathalia V Porhanova; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2009-02-25       Impact factor: 2.857

7.  Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.

Authors:  Cécile Le Page; David G Huntsman; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Cancers (Basel)       Date:  2010-05-26       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.